Evicenter
MarkdownMedical informationP&T meetings
Ersodetug (RZ358)

Tumor hyperinsulinism

Manufacturer
Rezolute
Launch
Not announced
Last updated
140 sources

Executive summary

Budget impact of Ersodetug

1 evidence topic · 3 sources

Summary
  • Ersodetug is investigational and has no published price, and no budget impact model, cost-effectiveness analysis, or health technology assessment of ersodetug has been published.
  • The manufacturer estimates the U.S. eligible population at approximately 3,000 or approximately 4,000 patients per year (incidence) and about 2,500 malignant insulinoma plus about 1,500 NICTH patients (point-in-time prevalence as of October 2026), and assumes 9 vials per infusion and 117 vials per patient per year at the 9 mg/kg maintenance dose.
  • In the manufacturer's claims data, the primary payer was Medicare for 48.6% of patients, commercial insurance for 43.9%, Medicaid for 5.5%, and other payers for 2.0%. Its payer research anticipates prior authorization with a step through diazoxide for insulinoma and reimbursement through a J-code.